SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 145 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,032,952 | -40.1% | 71,140 | -13.7% | 0.00% | -50.0% |
| Q2 2023 | $1,724,381 | +46.6% | 82,388 | +47.9% | 0.00% | +100.0% |
| Q1 2023 | $1,176,363 | -15.4% | 55,699 | +1.9% | 0.00% | 0.0% |
| Q4 2022 | $1,390,639 | +28.1% | 54,642 | +20.9% | 0.00% | 0.0% |
| Q3 2022 | $1,086,000 | +72.4% | 45,199 | +38.1% | 0.00% | 0.0% |
| Q2 2022 | $630,000 | +22.1% | 32,732 | +10.4% | 0.00% | – |
| Q1 2022 | $516,000 | -23.0% | 29,639 | -3.2% | 0.00% | – |
| Q4 2021 | $670,000 | +31.9% | 30,604 | +15.0% | 0.00% | – |
| Q3 2021 | $508,000 | +23.6% | 26,611 | +11.1% | 0.00% | – |
| Q2 2021 | $411,000 | -28.9% | 23,945 | -7.5% | 0.00% | – |
| Q1 2021 | $578,000 | -53.2% | 25,893 | -53.4% | 0.00% | -100.0% |
| Q4 2020 | $1,235,000 | +36.0% | 55,516 | -9.8% | 0.00% | 0.0% |
| Q3 2020 | $908,000 | +17.9% | 61,575 | +18.6% | 0.00% | 0.0% |
| Q2 2020 | $770,000 | – | 51,934 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |